Search research articles
Contact Us
Filters
Showing results (11-20 of 37) with videos related to
Page
of 4
Sort By:
Clinical Advances in Hematology & Oncology : H&O
|
July 1, 2025
Navigating the paroxysmal nocturnal hemoglobinuria (PNH) landscape
Gloria F Gerber, Catherine M Broome, Ilene C Weitz
American Journal of Hematology
|
January 1, 2003
Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment
Douglas E Sutherland, Ilene C Weitz, Howard A Liebman
Clinical Advances in Hematology & Oncology : H&O
|
July 1, 2025
Practical approach to managing PNH: Q&A
Gloria F Gerber, Ilene C Weitz, Catherine M Broome
Platelets
|
March 28, 2018
Ethnic and racial difference in Helicobacter pylori infection in patients with immune thrombocytopenia treated at a major urban medical center
Caitlin M O'Neill, Ilene C Weitz, Casey O'Connell, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|
April 7, 2007
Successful rituximab therapy of acquired factor VIII inhibitor in a patient with rheumatoid arthritis
Bruno Oliveira, Daniel G Arkfeld, Ilene C Weitz, et al.
Blood Transfusion = Trasfusione Del Sangue
|
December 17, 2013
Atypical haemolytic-uraemic syndrome due to heterozygous mutations of CFH/CFHR1-3 and complement factor H 479
Preeti Chaudhary, Mehmet Hepgur, Sarmen Sarkissian, et al.
Blood Reviews
|
February 2, 2023
Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition
Austin G Kulasekararaj, David J Kuter, Morag Griffin, et al.
Acta Haematologica
|
October 31, 2019
A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia
Caroline I Piatek, Hillel Bocian, Sandra Algaze, et al.
Investigational New Drugs
|
November 27, 2002
Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group study
Cary A Presant, Joth Jacobson, Walter Wolf, et al.
Transfusion
|
May 20, 2015
Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab
Mark Boonyasampant, Ilene C Weitz, Brian Kay, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 37) with videos related to
Sort By:
Page
of 4
Clinical Advances in Hematology & Oncology : H&O
|
July 1, 2025
Navigating the paroxysmal nocturnal hemoglobinuria (PNH) landscape
Gloria F Gerber, Catherine M Broome, Ilene C Weitz
American Journal of Hematology
|
January 1, 2003
Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment
Douglas E Sutherland, Ilene C Weitz, Howard A Liebman
Clinical Advances in Hematology & Oncology : H&O
|
July 1, 2025
Practical approach to managing PNH: Q&A
Gloria F Gerber, Ilene C Weitz, Catherine M Broome
Platelets
|
March 28, 2018
Ethnic and racial difference in Helicobacter pylori infection in patients with immune thrombocytopenia treated at a major urban medical center
Caitlin M O'Neill, Ilene C Weitz, Casey O'Connell, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|
April 7, 2007
Successful rituximab therapy of acquired factor VIII inhibitor in a patient with rheumatoid arthritis
Bruno Oliveira, Daniel G Arkfeld, Ilene C Weitz, et al.
Blood Transfusion = Trasfusione Del Sangue
|
December 17, 2013
Atypical haemolytic-uraemic syndrome due to heterozygous mutations of CFH/CFHR1-3 and complement factor H 479
Preeti Chaudhary, Mehmet Hepgur, Sarmen Sarkissian, et al.
Blood Reviews
|
February 2, 2023
Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition
Austin G Kulasekararaj, David J Kuter, Morag Griffin, et al.
Acta Haematologica
|
October 31, 2019
A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia
Caroline I Piatek, Hillel Bocian, Sandra Algaze, et al.
Investigational New Drugs
|
November 27, 2002
Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group study
Cary A Presant, Joth Jacobson, Walter Wolf, et al.
Transfusion
|
May 20, 2015
Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab
Mark Boonyasampant, Ilene C Weitz, Brian Kay, et al.
Page
of 4